Document is current
Any future updates will be listed below
-
Authors
Chan, Tsz-Yin
Egbert, Christina M.
Maxson, Julia E. https://orcid.org/0000-0002-3871-7221
Siddiqui, Adam
Larsen, Logan J.
Kohler, Kristina
Balasooriya, Eranga Roshan https://orcid.org/0000-0002-5491-3089
Pennington, Katie L. https://orcid.org/0000-0003-2883-0025
Tsang, Tsz-Ming
Frey, Madison
Soderblom, Erik J.
Geng, Huimin
Müschen, Markus https://orcid.org/0000-0002-6064-8613
Forostyan, Tetyana V.
Free, Savannah
Mercenne, Gaelle
Banks, Courtney J. https://orcid.org/0000-0002-7079-506X
Valdoz, Jonard https://orcid.org/0000-0002-7106-1009
Whatcott, Clifford J.
Foulks, Jason M.
Bearss, David J.
O’Hare, Thomas
Huang, David C. S. https://orcid.org/0000-0002-3101-4873
Christensen, Kenneth A. https://orcid.org/0000-0002-3736-5500
Moody, James https://orcid.org/0000-0003-2266-5348
Warner, Steven L.
Tyner, Jeffrey W. https://orcid.org/0000-0002-2133-0960
Andersen, Joshua L. https://orcid.org/0000-0003-2071-744X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R00 CA190605, 2R15CA202618-02)
American Cancer Society (RSG-19-184-01)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 27 July 2020
Accepted: 20 August 2021
First Online: 9 September 2021
Competing interests
: J.L.A declares competing interests in the form of consulting for Sumitomo Dainippon Pharma Oncology. Authors affiliated with Sumitomo Dainippon Pharma Oncology have a financial stake in the development of the TNK1 inhibitor. The remaining authors declare no competing interests.
